(PDF) P3.01-01 Prospective Comparison of Four Plasma

P3.01-01 Prospective Comparison of Four Plasma Testing Platforms for T790M and Effectiveness of Osimertinib in Chinese NSCLC Patients

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.1561

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P3.01-53 Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients With T790m-Positive NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

MA15.10 Loss of T790M Mutation Is Associated With Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

Journal of Thoracic Oncology

Respiratory Medicine

English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.01-06 Concomitant Plasma-Genotyped T790M Positivity and Small Cell Carcinoma Transformation in EGFR-Mutated NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients With EGFR T790m-Positive NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

A Comparison of QuantStudio™ 3D Digital PCR and ARMS-PCR for Measuring Plasma EGFR T790M Mutations of NSCLC Patients

Cancer Management and Research

English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English